Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451310 | 0.88 | CNR2 (0.49) | CNR2PDE10ADRD3CNR1 | |
| SCHEMBL5454595 | 0.87 | PDE10A (0.49) | CNR2PDE10AHTR7MEN1ALDH1A1 | |
| SCHEMBL5452085 | 0.86 | CNR2 (0.51) | CNR2PDE10AHTR7MEN1ALDH1A1 | |
| SCHEMBL5447102 | 0.86 | PDE10A (0.52) | CNR2PDE10ADRD3 | |
| SCHEMBL5450975 | 0.85 | PDE10A (0.47) | CNR2PDE10AHTR7ALDH1A1KMT2A | |
| SCHEMBL5452079 | 0.85 | PDE10A (0.48) | CNR2PDE10AHTR7MEN1ALDH1A1 | |
| SCHEMBL5450020 | 0.85 | CNR2 (0.48) | CNR2PDE10AKMT2ACNR1 | |
| SCHEMBL5453856 | 0.84 | CNR2 (0.49) | CNR2PDE10AALDH1A1DRD3 | |
| SCHEMBL5454395 | 0.83 | PDE10A (0.46) | CNR2PDE10AHTR7DRD3 | |
| SCHEMBL5451253 | 0.83 | CNR2 (0.47) | CNR2PDE10AALDH1A1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885PDE10A 514/4885HTR7 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.